Waters (NYSE: WAT) doubles 2026 revenue plan with BD Biosciences deal

Rhea-AI Filing Summary

Waters Corporation reported solid fourth quarter and full-year 2025 results and issued strong 2026 guidance alongside closing its acquisition of BD Biosciences and Diagnostic Solutions. Fourth quarter 2025 sales were $932 million, up 7%, with non-GAAP EPS up 10% to $4.53, while GAAP diluted EPS slipped slightly to $3.77.

For full-year 2025, sales grew 7% to $3.17 billion, GAAP EPS was $10.76 versus $10.71, and non-GAAP EPS rose 11% to $13.13. Growth was led by pharmaceutical and industrial markets and by recurring service and chemistry revenues. Cash and cash equivalents increased to $587.8 million, and debt declined to $1.41 billion.

For 2026, Waters expects total reported revenue of $6.41–$6.46 billion including about $3.0 billion from the acquired BD businesses and revenue synergies, with organic reported revenue of $3.36–$3.41 billion. Full-year 2026 non-GAAP EPS is guided to $14.30–$14.50, implying roughly 8.9–10.4% growth, while GAAP EPS is projected at $6.63–$6.83 due to acquisition-related charges.

Positive

• Strong non-GAAP earnings growth and outlook: 2025 non-GAAP EPS rose 11% to $13.13, and 2026 non-GAAP EPS is guided to $14.30–$14.50, implying roughly 8.9–10.4% additional growth on a much larger revenue base.
• Transformative revenue scale from BD acquisition: 2026 total reported revenue is projected at $6.405–$6.455 billion, including about $3.0 billion from the acquired Biosciences and Diagnostic Solutions businesses, roughly doubling the company’s 2025 sales.

Negative

• Lower projected GAAP profitability post-acquisition: 2026 GAAP EPS is guided to $6.63–$6.83, well below 2025 GAAP EPS of $10.76, reflecting significant acquisition-related amortization and costs that materially reduce reported earnings.

Insights

Equity research analyst

Waters posts steady 2025 growth and guides to much larger, higher-earnings 2026 after the BD Biosciences and Diagnostic Solutions acquisition.

Waters Corporation grew 2025 net sales 7% to $3.17 billion, with non-GAAP EPS up 11% to $13.13. Growth was broad-based: pharmaceutical sales rose 9%, industrial 6%, and recurring service and chemistry revenues 8%, supporting more stable cash flows.

The company closed its combination with Becton, Dickinson’s Biosciences and Diagnostic Solutions business, transforming scale. For 2026, total reported revenue is guided to $6.405–$6.455 billion, including $3.0 billion from the acquired businesses, while organic constant-currency growth is targeted at 5.5–7.0%.

Non-GAAP EPS in 2026 is projected at $14.30–$14.50, about 8.9–10.4% growth, including modest accretion from the BD assets. GAAP EPS is expected to fall to $6.63–$6.83 because of sizable non-cash amortization and related acquisition costs, so headline profitability will depend heavily on non-GAAP adjustments and synergy execution.

WATERS CORP /DE/ NYSE false 0001000697 0001000697 2026-02-09 2026-02-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 9, 2026

Waters Corporation

(Exact Name of Registrant as Specified in its Charter)

Delaware		001-14010		13-3668640
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

34 Maple Street

Milford, Massachusetts 01757

(Address of Principal Executive Offices) (Zip Code)

(508) 478-2000

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.01 per share		WAT		New York Stock Exchange, Inc.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On February 9, 2026, Waters Corporation announced its results of operations for the quarter and year ended December 31, 2025. A copy of the related press release is furnished as Exhibit 99.1 to this Form 8-K.

The information contained in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

Exhibits
99.1		Waters Corporation press release dated February 9, 2026, for the quarter and year ended December 31, 2025.
104		Cover page Interactive Date File (embedded within the Inline XBRL document).

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				WATERS CORPORATION
Dated: February 9, 2026				By:		/s/ Amol Chaubal
				Name:		Amol Chaubal
				Title:		Senior Vice President and Chief Financial Officer
						(Principal Financial Officer and Principal Accounting Officer)

Exhibit 99.1

For Immediate Release

Contact: Caspar Tudor, Head of Investor Relations – (508) 482-3448

Waters Corporation (NYSE: WAT) Reports Fourth Quarter

and Full-Year 2025 Financial Results

Highlights

Fourth Quarter 2025

• Sales of $932 million landed at the high-end of reported sales growth guidance range; grew 7% as reported and 6% in constant currency

• Growth led by high single-digit constant currency growth in Pharma and Industrial end-markets, with broad-based growth across all regions

• Chemistry grew 12% in constant currency as new bioseparations products continued to experience significant customer demand

• Instruments grew 3% in constant currency, with high single-digit LC-MS growth partially offset by TA and transition to subscription model for Empower

• GAAP EPS of $3.77; non-GAAP EPS of $4.53 grew double digits

Full-Year 2025

• Sales of $3,165 million grew 7% as reported and 7% in constant currency

• Instruments grew 5% in constant currency, led by strong LC-MS growth

• Recurring Revenue grew 8% in constant currency, led by 12% Chemistry growth

• GAAP EPS of $10.76; non-GAAP EPS of $13.13 grew double digits

MILFORD, Mass., February 9, 2026 - Waters Corporation (NYSE: WAT), today announced its financial results for the fourth quarter and full year 2025.

Sales for the fourth quarter of 2025 were $932 million, an increase of 7% as reported and 6% in constant currency, compared to sales of $873 million for the fourth quarter of 2024.

On a GAAP basis, diluted earnings per share (EPS) for the fourth quarter of 2025 were $3.77, compared to $3.88 for the fourth quarter of 2024. Non-GAAP EPS for the fourth quarter of 2025 grew 10% to $4.53, compared to $4.10 for the fourth quarter of 2024.

“Our team delivered industry-leading results in 2025, achieving high single-digit revenue growth and double-digit adjusted EPS growth. We expect this momentum to continue into 2026, driven by strong execution of the multi-year instrument replacement cycle, continued contribution from pioneering innovation, and our Waters-specific idiosyncratic growth drivers,” said Udit Batra, Ph.D., President & Chief Executive Officer, Waters Corporation.

“As we enter 2026, the addition of BD Biosciences and Diagnostic Solutions marks a transformative step forward for Waters. Today, we will close the transaction and are launching commercial excellence initiatives tied to instrument replacement, e-commerce, and service attachment that will build momentum and drive the first phase of our stated revenue synergies. Within the P&L, we also expect to make decisive progress towards realizing our stated cost synergies in the months ahead. Our starting 2026 guidance calls for an attractive 5.3% combined company sales growth at mid-point, with opportunity for outperformance as the year progresses.”

Fourth Quarter 2025

During the fourth quarter of 2025, sales into the pharmaceutical market increased 8% as reported and 7% in constant currency. Sales into the industrial market increased 8% as reported and in constant currency. Sales into the academic and government market decreased 2% as reported and 3% in constant currency.

During the quarter, instrument system sales increased 3% as reported and in constant currency. Recurring revenues, which represent the combination of service and precision chemistries, increased 10% as reported and 9% in constant currency.

Geographically, sales in Asia during the quarter increased 4% as reported and 11% in constant currency. Sales in the Americas increased 4% as reported and in constant currency. Sales in Europe increased 13% as reported and 4% in constant currency.

Full-Year 2025

Sales for the fiscal year 2025 were $3,165 million, an increase of 7% as reported and in constant currency, compared to sales of $2,958 million for fiscal year 2024.

On a GAAP basis, EPS for fiscal year 2025 was $10.76 compared to $10.71 for fiscal year 2024. On a non-GAAP basis, EPS increased by 11% to $13.13 compared to $11.86 for fiscal year 2024.

During the fiscal year 2025, sales into the pharmaceutical market increased 9% as reported and in constant currency. Sales into the industrial market increased 6% as reported and in constant currency. Sales into the academic and government market were flat as reported and decreased 1% in constant currency.

During the year, instrument system sales increased 5% as reported and in constant currency. Recurring revenues, which represent the combination of service and precision chemistries, increased 8% as reported and in constant currency.

Geographically, sales in Asia during the year increased 7% as reported and 13% in constant currency. Sales in the Americas increased 4% as reported and in constant currency. Sales in Europe increased 10% as reported and 5% in constant currency.

Unless otherwise noted, sales growth and decline percentages are presented on an as-reported basis. A description and reconciliation of GAAP to non-GAAP results appear in the tables below and can be found on the Company’s website www.waters.com in the Investor Relations section.

Full-Year and First Quarter 2026 Financial Guidance

Full-Year 2026 Financial Guidance

The Company expects full-year 2026 organic constant currency revenue growth to be in the range of +5.5% to +7.0%. Including the positive impact of currency translation, full-year 2026 organic reported revenue is expected to be in the range of $3.355 billion to $3.405 billion.

The Company expects an acquired business contribution in full-year 2026 of approximately $3.000 billion to reported revenue on an owned-period basis.

Including the positive impact of expected revenue synergies, total Company revenue for full-year 2026 is expected to be in the range of $6.405 billion to $6.455 billion on a reported basis.

The Company expects full-year 2026 non-GAAP EPS to be in the range of $14.30 to $14.50, which includes $0.10 cents of accretion versus the Company’s standalone non-GAAP EPS profile due to our combination with the Biosciences and Diagnostic Solutions business of Becton, Dickinson & Company. This represents year-over-year non-GAAP EPS growth of approximately +8.9% to +10.4% for full-year 2026.

First Quarter 2026 Financial Guidance

The Company expects first quarter 2026 organic constant currency revenue growth to be in the range of +7.0% to +9.0%. Including the positive impact of currency translation, first quarter 2026 organic reported revenue is expected to be in the range of $718 million to $731 million.

The Company expects an acquired business contribution in the first quarter of 2026 of approximately $480 million to reported revenue on an owned-period basis.

Total Company revenue for the first quarter of 2026 is expected to be in the range of $1.198 billion to $1.211 billion on a reported basis.

The Company expects first quarter 2026 non-GAAP EPS to be in the range of $2.25 to $2.35, which reflects year-over-year growth of approximately +0.0% to +4.4%.

Please refer to the tables below for a reconciliation of the projected GAAP to non-GAAP financial outlook for the full-year and first quarter.

Conference Call Details

Waters Corporation will webcast its fourth quarter 2025 financial results conference call today, February 9, 2026, at 8:30 a.m. Eastern Time. To listen to the call and see the accompanying slide presentation, please visit www.waters.com, select “Investor Relations” under the “About Waters” section, navigate to “Events & Presentations,” and click on the “Webcast.” A replay will be available through at least March 9, 2026.

About Waters Corporation

Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of food and the purity of water, and the quality and sustainability of products used every day. In over 100 countries, our 7,900+ passionate employees collaborate with customers in laboratories, manufacturing sites, and hospitals to accelerate the benefits of pioneering science.

Non-GAAP Financial Measures

This release contains financial measures, such as organic constant currency growth rates, constant currency growth rates and adjusted earnings per diluted share, among others, which are considered “non-GAAP” financial measures under applicable U.S. Securities and Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP). The Company’s definitions of these non-GAAP measures may differ from similarly titled measures used by others. The non-GAAP financial measures used in this release adjust for specified items that can be highly variable or difficult to predict. The Company generally uses these non-GAAP financial measures to facilitate management’s financial and operational decision-making, including evaluation of the Company’s historical operating results, comparison to competitors’ operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company’s business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety. Definitions of the non-GAAP financial measures and reconciliations to the most directly comparable GAAP financial measures are included in the tables accompanying this release.

Cautionary Statement

This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “feels”, “believes”, “anticipates”, “plans”, “expects”, “intends”, “suggests”, “appears”, “estimates”, “projects” and similar expressions, whether in the negative or affirmative, are intended to identify forward-looking statements. Our actual results may differ significantly from the results discussed in the forward-looking statements within this release for a variety of reasons, including and without limitation, risks or uncertainties related to our acquisition of Becton, Dickinson and Company’s Biosciences and Diagnostic Solutions business, the impact of this acquisition on the Company’s business and future results, including unexpected costs, charges or expenses resulting from this acquisition as well as difficulties and delays in achieving expected revenue and cost synergies related to this acquisition, the increased indebtedness of the Company as a result of this acquisition, our future financial and operational performance, future economic and market conditions, including our expectations about the growth rates of certain markets, our strategic initiatives, including our instrument replacement initiatives, respond and adapt to changing global dynamics, including the potential impacts of tariffs and supply chain challenges, our ability to retain and attract customers in various geographies and market segments, our market size and growth opportunities, our competitive

positioning, projected costs, technological capabilities and plans, and objectives of management, and other risk factors detailed from time to time in Waters’ reports filed with the Securities and Exchange Commission (“SEC”). Such factors and others are discussed more fully in the sections entitled “Forward-Looking Statements” and “Risk Factors” of the Company’s annual report on Form 10-K for the year ended December 31, 2024, as filed with the SEC, which discussions are incorporated by reference in this release, as updated by the Company’s subsequent filings with the SEC. The forward-looking statements included in this release represent the Company’s estimates or views as of the date of this release and should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this release. Except as required by law, the Company does not assume any obligation to update any forward-looking statements.

Waters Corporation and Subsidiaries

Consolidated Statements of Operations

(In thousands, except per share data)

(Unaudited)

		Three Months Ended								Twelve Months Ended
		December 31, 2025				December 31, 2024				December 31, 2025				December 31, 2024
Net sales		$	932,362			$	872,714			$	3,165,286			$	2,958,387
Costs and operating expenses:
Cost of sales			362,864				348,516				1,288,822				1,200,201
Selling and administrative expenses			240,007				173,268				830,374				690,148
Research and development expenses			46,898				46,914				195,711				183,027
Purchased intangibles amortization			12,077				11,753				47,791				47,090
Litigation provision			—				—				—				11,568
Operating income			270,516				292,263				802,588				826,353
Other income (expense), net			2,283				(843	)			3,061				776
Interest expense, net			(8,618	)			(14,437	)			(50,771	)			(72,261	)
Income from operations before income taxes			264,181				276,983				754,878				754,868
Provision for income taxes			38,967				45,585				112,249				117,034
Net income		$	225,214			$	231,398			$	642,629			$	637,834
Net income per basic common share		$	3.78			$	3.90			$	10.80			$	10.75
Weighted-average number of basic common shares			59,546				59,386				59,509				59,333
Net income per diluted common share		$	3.77			$	3.88			$	10.76			$	10.71
Weighted-average number of diluted common shares and equivalents			59,763				59,645				59,706				59,552

Waters Corporation and Subsidiaries

Reconciliation of GAAP to Adjusted Non-GAAP

Net Sales by Operating Segments, Products & Services, Geography and Markets

Three Months Ended December 31, 2025 and December 31, 2024

(In thousands)

		Three Months Ended								Percent Change				Impact of Currency				Constant Currency Growth Rate (a)
		December 31, 2025				December 31, 2024
NET SALES - OPERATING SEGMENTS
Waters		$	823,937			$	764,309				8	%			1	%			7	%
TA			108,425				108,405				0	%			0	%			0	%
Total		$	932,362			$	872,714				7	%			1	%			6	%
NET SALES - PRODUCTS & SERVICES
Instruments		$	432,850			$	419,616				3	%			1	%			3	%
Service			329,156				301,844				9	%			1	%			8	%
Chemistry			170,356				151,254				13	%			1	%			12	%
Total Recurring			499,512				453,098				10	%			1	%			9	%
Total		$	932,362			$	872,714				7	%			1	%			6	%
NET SALES - GEOGRAPHY
Asia		$	283,967			$	272,903				4	%			(7	%)			11	%
Americas			332,424				321,005				4	%			0	%			4	%
Europe			315,971				278,806				13	%			9	%			4	%
Total		$	932,362			$	872,714				7	%			1	%			6	%
NET SALES - MARKETS
Pharmaceutical		$	540,567			$	498,807				8	%			1	%			7	%
Industrial			284,465				264,027				8	%			0	%			8	%
Academic & Government			107,330				109,880				(2	%)			1	%			(3	%)
Total		$	932,362			$	872,714				7	%			1	%			6	%

(a) The Company believes that referring to comparable constant currency growth rates is a useful way to evaluate the underlying performance of Waters Corporation’s net sales. Constant currency growth, a non-GAAP financial measure, measures the change in net sales between current and prior year periods, excluding the impact of foreign currency exchange rates during the current period. See description of non-GAAP financial measures contained in this release.

Waters Corporation and Subsidiaries 

Reconciliation of GAAP to Adjusted Non-GAAP 

Net Sales by Operating Segments, Products & Services, Geography and Markets 

Twelve Months Ended December 31, 2025 and December 31, 2024 

(In thousands) 

		Twelve Months Ended								Percent Change				Impact of Currency				Constant Currency Growth Rate (a)
		December 31, 2025				December 31, 2024
NET SALES - OPERATING SEGMENTS
Waters		$	2,813,446			$	2,604,421				8	%			0	%			8	%
TA			351,840				353,966				(1	%)			0	%			(1	%)
Total		$	3,165,286			$	2,958,387				7	%			0	%			7	%
NET SALES - PRODUCTS & SERVICES
Instruments		$	1,345,642			$	1,278,695				5	%			0	%			5	%
Service			1,188,186				1,114,211				7	%			0	%			7	%
Chemistry			631,458				565,481				12	%			0	%			12	%
Total Recurring			1,819,644				1,679,692				8	%			0	%			8	%
Total		$	3,165,286			$	2,958,387				7	%			0	%			7	%
NET SALES - GEOGRAPHY
Asia		$	1,040,397			$	969,222				7	%			(5	%)			13	%
Americas			1,161,513				1,115,780				4	%			0	%			4	%
Europe			963,376				873,385				10	%			6	%			5	%
Total		$	3,165,286			$	2,958,387				7	%			0	%			7	%
NET SALES - MARKETS
Pharmaceutical		$	1,873,362			$	1,718,899				9	%			0	%			9	%
Industrial			961,154				908,486				6	%			0	%			6	%
Academic & Government			330,770				331,002				0	%			1	%			(1	%)
Total		$	3,165,286			$	2,958,387				7	%			0	%			7	%

(a) The Company believes that referring to comparable constant currency growth rates is a useful way to evaluate the underlying performance of Waters Corporation’s net sales. Constant currency growth, a non-GAAP financial measure, measures the change in net sales between current and prior year periods, excluding the impact of foreign currency exchange rates during the current period. See description of non-GAAP financial measures contained in this release.

Waters Corporation and Subsidiaries

Reconciliation of GAAP to Adjusted Non-GAAP Financials

Three and Twelve Months Ended December 31, 2025 and December 31, 2024

(In thousands, except per share data)

		Selling & Administrative Expenses(a)				Research & Development Expenses				Operating Income				Operating Income Percentage				Other Income (Expense)				Interest Expense, Net				Income from Operations before Income Taxes				Provision for Income Taxes				Net Income				Diluted Earnings per Share
Three Months Ended December 31, 2025
GAAP		$	252,084			$	46,898			$	270,516				29.0	%		$	2,283			$	(8,618	)		$	264,181			$	38,967			$	225,214			$	3.77
Adjustments:
Purchased intangibles amortization (b)			(12,077	)			—				12,077				1.3	%			—				—				12,077				2,930				9,147				0.15
Restructuring costs and certain other items (c)			(3,290	)			—				3,290				0.4	%			(2,398	)			—				892				216				676				0.01
ERP implementation and transformation costs (d)			(5,777	)			—				5,777				0.6	%			—				—				5,777				1,386				4,391				0.07
Acquisition related costs (e)			(39,975	)			3,204				36,771				3.9	%			—				—				36,771				6,589				30,182				0.51
Financing Costs (h)			—				—				—				—				—				1,518				1,518				364				1,154				0.02
Adjusted Non-GAAP		$	190,965			$	50,102			$	328,431				35.2	%		$	(115	)		$	(7,100	)		$	321,216			$	50,452			$	270,764			$	4.53
Three Months Ended December 31, 2024
GAAP		$	185,021			$	46,914			$	292,263				33.5	%		$	(843	)		$	(14,437	)		$	276,983			$	45,585			$	231,398			$	3.88
Adjustments:
Purchased intangibles amortization (b)			(11,753	)			—				11,753				1.3	%			—				—				11,753				2,813				8,940				0.15
Restructuring costs and certain other items (c)			(1,480	)			—				1,480				0.2	%			—				—				1,480				354				1,126				0.02
ERP implementation and transformation costs (d)			(1,346	)			—				1,346				0.2	%			—				—				1,346				337				1,009				0.02
Retention bonus obligation (g)			(1,911	)			(636	)			2,547				0.3	%			—				—				2,547				612				1,935				0.03
Adjusted Non-GAAP		$	168,531			$	46,278			$	309,389				35.5	%		$	(843	)		$	(14,437	)		$	294,109			$	49,701			$	244,408			$	4.10
Twelve Months Ended December 31, 2025
GAAP		$	878,165			$	195,711			$	802,588				25.4	%		$	3,061			$	(50,771	)		$	754,878			$	112,249			$	642,629			$	10.76
Adjustments:
Purchased intangibles amortization (b)			(47,791	)			—				47,791				1.5	%			—				—				47,791				11,476				36,315				0.61
Restructuring costs and certain other items (c)			(9,036	)			—				9,036				0.3	%			(2,398	)			—				6,638				1,560				5,078				0.09
ERP implementation and transformation costs (d)			(19,588	)			—				19,588				0.6	%			—				—				19,588				4,701				14,887				0.25
Acquisition related costs (e)			(81,068	)			(531	)			81,599				2.6	%			—				—				81,599				11,318				70,281				1.18
Retention bonus obligation (g)			(2,864	)			(954	)			3,818				0.1	%			—				—				3,818				916				2,902				0.05
Financing Costs (h)			—				—				—				—				—				15,578				15,578				3,738				11,840				0.20
Adjusted Non-GAAP		$	717,818			$	194,226			$	964,420				30.5	%		$	663			$	(35,193	)		$	929,890			$	145,958			$	783,932			$	13.13
Twelve Months Ended December 31, 2024
GAAP		$	748,806			$	183,027			$	826,353				27.9	%		$	776			$	(72,261	)		$	754,868			$	117,034			$	637,834			$	10.71
Adjustments:
Purchased intangibles amortization (b)			(47,090	)			—				47,090				1.6	%			—				—				47,090				11,269				35,821				0.60
Restructuring costs and certain other items (c)			(12,160	)			—				12,160				0.4	%			—				—				12,160				2,971				9,189				0.15
ERP implementation and transformation costs (d)			(1,346	)			—				1,346				0.0	%			—				—				1,346				337				1,009				0.02
Litigation provision and settlement (f)			(11,568	)			—				11,568				0.4	%			—				—				11,568				2,776				8,792				0.15
Retention bonus obligation (g)			(13,362	)			(4,453	)			17,815				0.6	%			—				—				17,815				4,276				13,539				0.23
Adjusted Non-GAAP		$	663,280			$	178,574			$	916,332				31.0	%		$	776			$	(72,261	)		$	844,847			$	138,663			$	706,184			$	11.86

(a) Selling & administrative expenses include purchased intangibles amortization and litigation provisions and settlements.

(b) The purchased intangibles amortization, a non-cash expense, was excluded to be consistent with how management evaluates the performance of its core business against historical operating results and the operating results of competitors over periods of time.

(c) Restructuring costs and certain other items were excluded as the Company believes that the cost to consolidate operations, reduce overhead, and certain other income or expense items are not normal and do not represent future ongoing business expenses of a specific function or geographic location of the Company.

(d) ERP implementation and transformation costs represent costs related to the Company’s initiative to transition from its legacy enterprise resource planning (ERP) system to a new global ERP solution with a cloud-based infrastructure. These costs, which do not represent normal or future ongoing business expenses, are one-time, non-recurring costs related to the establishment of our new global ERP solution that were determined to be non-capitalizable in accordance with accounting standards.

(e) Acquisition related costs include all incremental costs incurred to effect the business combination, such as advisory, legal, accounting, tax, valuation, other professional fees, and integration costs. The Company believes that these costs are not normal and do not represent future ongoing business expenses.

(f) Litigation provisions and settlement gains were excluded as these items are isolated, unpredictable and not expected to recur regularly.

(g) In connection with the Wyatt acquisition, the Company recognized a two-year retention bonus obligation that is contingent upon the employee’s providing future service and continued employment with Waters. The Company believes that these costs are not normal and do not represent future ongoing business expenses.

(h) Financing costs relate to certain financing fees incurred by the Company to secure access to certain debt facilities in connection with the agreement Waters entered into to acquire the Biosciences and Diagnostics Solutions business of Becton, Dickinson & Company. The Company believes that these costs are not normal and do not represent future ongoing business expenses.

Waters Corporation and Subsidiaries

Preliminary Condensed Unclassified Consolidated Balance Sheets

(In thousands and unaudited)

		December 31, 2025				December 31, 2024
Cash and cash equivalents		$	587,831			$	325,355
Accounts receivable			828,844				733,365
Inventories			572,371				477,261
Property, plant and equipment, net			642,046				651,200
Intangible assets, net			558,179				567,906
Goodwill			1,340,081				1,295,720
Other assets			554,625				502,988
Total assets		$	5,083,977			$	4,553,795
Notes payable and debt		$	1,407,445			$	1,626,488
Other liabilities			1,115,290				1,098,800
Total liabilities			2,522,735				2,725,288
Total stockholders’ equity			2,561,242				1,828,507
Total liabilities and stockholders’ equity		$	5,083,977			$	4,553,795

Waters Corporation and Subsidiaries

Preliminary Condensed Consolidated Statements of Cash Flows

Three and Twelve Months Ended December 31, 2025 and December 31, 2024

(In thousands and unaudited)

		Three Months Ended								Twelve Months Ended
		December 31, 2025				December 31, 2024				December 31, 2025				December 31, 2024
Cash flows from operating activities:
Net income		$	225,214			$	231,398			$	642,629			$	637,834
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation			14,502				11,716				54,127				44,709
Depreciation and amortization			52,541				48,575				206,237				191,825
Change in operating assets and liabilities and other, net			(127,704	)			(51,550	)			(250,438	)			(112,245	)
Net cash provided by operating activities			164,553				240,139				652,555				762,123
Cash flows from investing activities:
Additions to property, plant, equipment and software capitalization			(38,973	)			(52,104	)			(112,745	)			(142,481	)
Business acquisitions, net of cash acquired			—				—				(35,053	)			—
Investments in unaffiliated companies			(6,000	)			—				(7,295	)			(1,489	)
Net change in investments			—				(9	)			—				(53	)
Other cash flow from investing activities, net			2,840				—				2,840
Net cash used in investing activities			(42,133	)			(52,113	)			(152,253	)			(144,023	)
Cash flows from financing activities:
Net change in debt			(335	)			(200,000	)			(243,321	)			(730,000	)
Proceeds from stock plans			5,169				5,293				20,790				30,366
Purchases of treasury shares			(144	)			(66	)			(14,667	)			(13,541	)
Other cash flow from financing activities, net			(1,354	)			1,195				(7	)			16,500
Net cash provided by (used in) financing activities			3,336				(193,578	)			(237,205	)			(696,675	)
Effect of exchange rate changes on cash and cash equivalents			2,957				(541	)			(621	)			7,920
Increase (decrease) in cash and cash equivalents			128,713				(6,093	)			262,476				(70,655	)
Cash and cash equivalents at beginning of period			459,118				330,514				325,355				395,076
Cash and cash equivalents at end of period		$	587,831			$	324,421			$	587,831			$	324,421
Reconciliation of GAAP Cash Flows from Operating Activities to Free Cash Flow (a)
Net cash provided by operating activities - GAAP		$	164,553			$	240,139			$	652,555			$	762,123
Adjustments:
Additions to property, plant, equipment and software capitalization			(38,973	)			(52,104	)			(112,745	)			(142,481	)
Tax reform payments			—				—				120,006				95,645
Litigation settlements (received) paid, net			(375	)			—				(2,625	)			9,250
Payment of Wyatt retention bonus obligation (b)			—				—				20,127				19,770
Free Cash Flow - Adjusted Non-GAAP		$	125,205			$	188,035			$	677,318			$	744,307

(a) The Company defines free cash flow as net cash flow from operations accounted for under GAAP less capital expenditures and software capitalizations plus or minus any unusual and non recurring items. Free cash flow is not a GAAP measurement and may not be comparable to free cash flow reported by other companies.

(b) During the twelve months ended December 31, 2025 and 2024, the Company made retention payments under the Wyatt retention bonus program. The Company believes that these payments are not normal and do not represent future ongoing business expenses.

Waters Corporation and Subsidiaries

Reconciliation of Projected GAAP to Adjusted Non-GAAP Financial Outlook

(In millions, except per share data)

		Twelve Months Ended December 31, 2026												Three Months Ended April 4, 2026
		Range												Range
Projected revenue
Reported revenue		$	6,405				-			$	6,455			$	1,198				-			$	1,211
Impact of:
Acquired business contribution		$	3,000				-			$	3,000			$	480				-			$	480
Revenue synergies		$	50				-			$	50			$	—				-			$	—
Organic reported revenue		$	3,355				-			$	3,405			$	718				-			$	731
Organic reported revenue growth			6.0	%			-				7.5	%			8.5	%			-				10.5	%
Currency translation impact			0.5	%			-				0.5	%			1.5	%			-				1.5	%
Organic constant currency revenue growth (a)			5.5	%			-				7.0	%			7.0	%			-				9.0	%
		Range												Range
Projected Earnings Per Diluted Share
GAAP earnings per diluted share		$	6.63				-			$	6.83			$	0.05				-			$	0.15
Adjustments:
Purchased intangibles amortization		$	5.24				-			$	5.24			$	1.05				-			$	1.05
ERP implementation and transformation costs		$	0.14				-			$	0.14			$	0.06				-			$	0.06
Acquisition related costs		$	0.45				-			$	0.45			$	0.45				-			$	0.45
Amortization of acquisition-related inventory fair value step-up		$	1.84				-			$	1.84			$	0.64				-			$	0.64
Adjusted non-GAAP earnings per diluted share		$	14.30				-			$	14.50			$	2.25				-			$	2.35

(a) Organic constant currency growth rates are a non-GAAP financial measure that measures the change in net revenue between current and prior year periods, excluding the impact of foreign currency exchange rates during the current period and excluding the impact of acquisitions made within twelve months of the acquisition close date. These amounts are estimated at the current foreign currency exchange rates and based on the forecasted geographical revenue in local currency, as well as an assessment of market conditions as of the date of this press release, and may differ significantly from actual results.

These forward-looking adjustment estimates do not reflect future gains and charges that are inherently difficult to predict and estimate due to their unknown timing, effect and/or significance.

FAQ

How did Waters (WAT) perform financially in full-year 2025?

Waters delivered solid 2025 results, with net sales rising 7% to $3.17 billion and GAAP EPS of $10.76. Non-GAAP EPS grew 11% to $13.13, driven by 9% pharmaceutical market growth and 8% recurring service and chemistry revenue growth.

What were Waters (WAT) fourth quarter 2025 earnings and revenue?

In Q4 2025, Waters generated $932 million in sales, up 7% year over year. GAAP diluted EPS was $3.77, slightly below $3.88 a year earlier, while non-GAAP EPS increased 10% to $4.53, supported by strong recurring revenue growth and solid pharmaceutical demand.

What guidance did Waters (WAT) provide for full-year 2026?

For 2026, Waters expects total reported revenue of $6.405–$6.455 billion, including about $3.0 billion from acquired BD businesses. Organic constant-currency revenue growth is targeted at 5.5–7.0%, with non-GAAP EPS projected at $14.30–$14.50 and GAAP EPS at $6.63–$6.83.

How does the BD Biosciences and Diagnostic Solutions acquisition affect Waters (WAT)?

The acquisition adds about $3.0 billion of 2026 revenue on an owned-period basis, nearly doubling Waters’ 2025 sales. Management also expects revenue synergies and about $0.10 of non-GAAP EPS accretion in 2026 versus the standalone profile, alongside planned cost synergies.

How are Waters (WAT) revenues trending by market and geography?

In 2025, pharmaceutical sales grew 9%, industrial 6%, and academic and government were roughly flat. Geographically, Asia sales rose 7% as reported, Americas 4%, and Europe 10%. Recurring revenues from service and chemistry increased 8%, outpacing instrument growth.

What is Waters (WAT) cash and debt position after 2025?

At December 31, 2025, Waters held $587.8 million in cash and cash equivalents, up from $325.4 million a year earlier. Notes payable and debt decreased to $1.41 billion from $1.63 billion, while total stockholders’ equity increased to $2.56 billion.